{"product_id":"alopecia-areata-explained-a-patients-guide-to-autoimmune-hair-loss-diagnosis-and-modern-treatments","title":"Alopecia Areata Explained: A Patient's Guide to Autoimmune Hair Loss, Diagnosis, and Modern Treatments","description":"\u003cp\u003eAlopecia areata (AA) is an autoimmune condition in which the body's own immune cells attack hair follicles. This causes unpredictable, patchy, non-scarring hair loss that affects roughly 2% of people worldwide — about 147 million individuals. This comprehensive review explains that AA arises from a complex mix of immune dysregulation, inherited genetic susceptibility, environmental triggers, and epigenetic changes. CD8+NKG2D+ T cells and the signaling molecules IFN-γ and IL-15 act as central drivers. The authors detail how diagnosis relies mainly on clinical examination supported by hair pull tests, dermoscopy, and biopsy. The authors compare conventional treatments — topical sensitizers, steroids, and immunosuppressants — with newer targeted drugs such as JAK inhibitors and PDE4 inhibitors. These newer targeted drugs act faster and show superior efficacy. The review also documents the heavy psychological toll of AA, noting that nearly 60% of patients experience psychological distress and face higher risks of other autoimmune diseases, hypertension, and high cholesterol.\u003c\/p\u003e\n\n\u003ch1\u003eAlopecia Areata- Pathogenesis, Diagnosis, and Therapies\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: What Is Alopecia Areata?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#epidemiology\"\u003eHow Common Is Alopecia Areata, and Who Does It Affect?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#hair-cycle\"\u003eThe Normal Hair Growth Cycle and \"Immune Privilege\"\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#pathogenesis\"\u003eWhat Causes Alopecia Areata? The Big Picture\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#immune-cells\"\u003eThe Immune Cells That Drive Alopecia Areata\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#cytokines\"\u003eCytokines: The Chemical Messengers Behind Hair Loss\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#diagnosis\"\u003eHow Alopecia Areata Is Diagnosed and Measured\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatments\"\u003eConventional Treatments: What Has Been Used for Decades\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#emerging\"\u003eEmerging Targeted Therapies: Biologics and Small Molecules\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What Researchers Still Cannot Explain\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003ePractical Recommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eAlopecia areata is an autoimmune, non-scarring hair loss affecting about 2% of people worldwide—roughly 147 million—and is the second most common hair loss disorder.\u003c\/li\u003e\n\u003cli\u003eDiagnosis is mainly clinical, supported by hair pull test, dermoscopy, or biopsy; the SALT score quantifies scalp hair loss severity.\u003c\/li\u003e\n\u003cli\u003eConventional treatments include topical sensitizers, steroids, and immunosuppressants; newer JAK and PDE4 inhibitors act faster and show superior efficacy.\u003c\/li\u003e\n\u003cli\u003eNearly 60% of patients experience psychological distress, and risks of other autoimmune diseases, hypertension, and high cholesterol are elevated.\u003c\/li\u003e\n\u003cli\u003eCurrent treatments relieve symptoms but do not cure; relapse is common, and immune memory cells persist at original hair loss sites.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: What Is Alopecia Areata?\u003c\/h2\u003e\n\n\u003cp\u003eAlopecia areata (AA) is an autoimmune condition — meaning the immune system mistakenly attacks the body's own tissue. In AA, that attack targets hair follicles, producing patchy or complete hair loss that does not leave scars (the medical term is \"nonscarring alopecia\"). It can affect the scalp, the body, or both.\u003c\/p\u003e\n\n\u003cp\u003eThe condition appears in several distinct clinical forms, and doctors classify patients partly by how much hair is lost and where:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatchy alopecia\u003c\/strong\u003e — one or more round bald spots\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOphiasis\u003c\/strong\u003e — a band of hair loss wrapping around the back and sides of the scalp\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSisaipho\u003c\/strong\u003e — hair loss that spares the edges of the scalp, the opposite pattern of ophiasis\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiffuse alopecia\u003c\/strong\u003e — widespread thinning rather than distinct patches\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePerinevoidal alopecia\u003c\/strong\u003e — hair loss clustering around a mole (nevus)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMarie Antoinette and Thomas More syndrome\u003c\/strong\u003e — named after historical figures described with this pattern\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAlopecia areata incognita (AAI)\u003c\/strong\u003e — sudden, extensive shedding that mimics other types of hair loss\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAlopecia totalis (AT)\u003c\/strong\u003e — complete loss of scalp hair\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAlopecia universalis (AU)\u003c\/strong\u003e — loss of all hair on the scalp and body\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAA affects people of every age, gender, and ethnicity. The authors emphasize that despite decades of research, the precise cause remains elusive (unclear), and that is exactly what complicates the search for a cure.\u003c\/p\u003e\n\n\u003cp\u003eCurrent treatments relieve symptoms but do not cure the disease. That gap leaves many patients facing ongoing financial strain and a reduced quality of life.\u003c\/p\u003e\n\n\u003ch2 id=\"epidemiology\"\u003eHow Common Is Alopecia Areata, and Who Does It Affect?\u003c\/h2\u003e\n\n\u003cp\u003eAA ranks as the \u003cstrong\u003esecond most common hair loss disorder worldwide\u003c\/strong\u003e. It affects approximately \u003cstrong\u003e2% of the population — roughly 147 million individuals\u003c\/strong\u003e — and projections suggest that number will keep growing.\u003c\/p\u003e\n\n\u003cp\u003ePrevalence rates (how many people have the condition at a given time) vary by geography and age. The incidence is higher in children than in adults, and rates are comparable between men and women.\u003c\/p\u003e\n\n\u003cp\u003eThe psychological burden is substantial and well documented. \u003cstrong\u003ePsychological distress affects nearly 60% of AA patients — about 6 in 10.\u003c\/strong\u003e Reported problems include anxiety, insomnia, and diminished self-esteem, and these difficulties are most severe in patients with extensive hair loss. Anxiety-related disorders appear more often in women than in men.\u003c\/p\u003e\n\n\u003cp\u003eAA also travels with other health conditions. Patients face an elevated risk of comorbidities (additional coexisting diseases), including:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eOther autoimmune disorders\u003c\/li\u003e\n  \u003cli\u003eHypertension (high blood pressure)\u003c\/li\u003e\n  \u003cli\u003eHyperlipidemia (high cholesterol and other blood fats)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis means AA is not simply a cosmetic concern. It is a systemic condition with measurable effects on mental and physical health.\u003c\/p\u003e\n\n\u003ch2 id=\"hair-cycle\"\u003eThe Normal Hair Growth Cycle and \"Immune Privilege\"\u003c\/h2\u003e\n\n\u003cp\u003eTo understand AA, it helps to understand normal hair growth. Hair does not grow continuously. Instead, each follicle cycles through three phases, and every follicle runs its own independent cycle:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnagen\u003c\/strong\u003e — the growth phase, when the hair actively lengthens\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCatagen\u003c\/strong\u003e — the regression phase, when growth stops and the follicle shrinks\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTelogen\u003c\/strong\u003e — the resting phase, before the hair eventually sheds\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eIn healthy people, hair follicles enjoy something called \u003cstrong\u003eimmune privilege (IP)\u003c\/strong\u003e. This is a protective shield that keeps the immune system from attacking the follicle — the same way the body protects certain delicate tissues from its own defenses. Immune privilege prevents immune cells from reacting to \"foreign\" or self-antigens (proteins the immune system could recognize as targets).\u003c\/p\u003e\n\n\u003cp\u003eIn AA, this protection breaks down. Specific triggers disrupt immune privilege, exposing self-antigens to the immune system. Once exposed, those antigens provoke an immune response.\u003c\/p\u003e\n\n\u003cp\u003eThe result is inflammation around the hair follicle, driven by \u003cstrong\u003eIFN-γ\u003c\/strong\u003e (interferon-gamma, an immune signaling protein), \u003cstrong\u003eCD8+ T cells\u003c\/strong\u003e (a type of killer immune cell), and other immune components. This inflammation forces the follicle to shift prematurely from the growth phase (anagen) into the resting phase (telogen), and it halts anagen progression at \u003cstrong\u003estage III\u003c\/strong\u003e. Hair loss follows.\u003c\/p\u003e\n\n\u003cp\u003eThe authors note that AA patients show this disruption across the board: follicles are pushed into premature telogen and catagen phases while anagen progression is arrested.\u003c\/p\u003e\n\n\u003ch2 id=\"pathogenesis\"\u003eWhat Causes Alopecia Areata? The Big Picture\u003c\/h2\u003e\n\n\u003cp\u003eAA is multifactorial — meaning no single cause explains it. Four major forces interact: immune dysregulation, genetic susceptibility, environmental factors, and epigenetic alterations.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGenetics plays a central role.\u003c\/strong\u003e Evidence comes from familial clustering (AA running in families) and associations with specific \u003cstrong\u003ehuman leukocyte antigen (HLA) alleles\u003c\/strong\u003e — inherited immune-system markers. \u003cstrong\u003eGenome-wide association studies (GWAS)\u003c\/strong\u003e, which scan the entire genetic code for disease-linked variations, have identified multiple susceptibility loci (regions of DNA associated with the disease). These findings reinforce the genetic basis of AA.\u003c\/p\u003e\n\n\u003cp\u003eThe dominant immunologic theory holds that AA arises from ectopic expression of hair follicle autoantigens. Ectopic expression means hair follicle proteins that are normally hidden become visible to the immune system. AA may also arise from localized inflammatory damage triggered by factors such as trauma, infection, or stress. This disrupts the follicle's immune privilege, upregulates \u003cstrong\u003eMHC class I and II antigens\u003c\/strong\u003e (major histocompatibility complex proteins that flag cells to the immune system), and culminates in autoimmune attack.\u003c\/p\u003e\n\n\u003cp\u003eEnvironmental factors can push a genetically vulnerable person toward disease. These include psychological stress, infections, and hormonal fluctuations.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEpigenetic modifications add another layer of complexity.\u003c\/strong\u003e Epigenetics refers to changes that affect how genes are switched on or off without altering the DNA sequence itself. In AA, two such changes matter: \u003cstrong\u003eDNA methylation\u003c\/strong\u003e and \u003cstrong\u003ehistone acetylation\u003c\/strong\u003e. Both can dysregulate immune responses and disrupt hair follicle cycling.\u003c\/p\u003e\n\n\u003ch2 id=\"immune-cells\"\u003eThe Immune Cells That Drive Alopecia Areata\u003c\/h2\u003e\n\n\u003cp\u003eThe review devotes substantial attention to the specific immune cells involved. Each plays a different role.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCD8+NKG2D+ T cells are the key players.\u003c\/strong\u003e These are cytotoxic T lymphocytes (CTL) — killer cells of the adaptive immune system that normally defend against viruses, bacteria, and tumors. In AA, a specialized subset expressing the NKG2D receptor accumulates around the follicular bulb (the base of the hair follicle) in affected skin.\u003c\/p\u003e\n\n\u003cp\u003eCD8 acts as a coreceptor that recognizes peptides presented by MHC class I proteins. NKG2D is an activating receptor found mainly on cytotoxic immune cells. Together, CD8+NKG2D+ T cells behave like a targeted strike force against the follicle.\u003c\/p\u003e\n\n\u003cp\u003eThe experimental evidence is striking:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eCD8+NKG2D+ T cells \u003cstrong\u003ealone\u003c\/strong\u003e can induce AA-like lesions in healthy human skin grafts placed in \u003cstrong\u003eSCID mice\u003c\/strong\u003e (mice with a severely compromised immune system that accept foreign tissue).\u003c\/li\u003e\n  \u003cli\u003eLevels of these cells rise in the body after disease onset.\u003c\/li\u003e\n  \u003cli\u003eIn a mouse model of AA, CD8+NKG2D+ T cells produce \u003cstrong\u003eIFN-γ\u003c\/strong\u003e through the \u003cstrong\u003eJAK1 and JAK2 pathways\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eThat IFN-γ then stimulates follicular epithelial cells (the cells lining the follicle) to release \u003cstrong\u003eIL-15\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eIL-15 binds back to the surface of CD8+NKG2D+ T cells through the \u003cstrong\u003eJAK1 and JAK3 pathways\u003c\/strong\u003e, triggering even more IFN-γ production.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis creates a \u003cstrong\u003epositive feedback loop\u003c\/strong\u003e — a self-reinforcing cycle of inflammation. The authors state these findings collectively confirm that CD8+NKG2D+ T cells are sufficient on their own to initiate AA.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCD4+ T cells\u003c\/strong\u003e are a different T lymphocyte subset, developing in the thymus. They carry the CD4 glycoprotein, which binds MHC class II molecules. CD4+ T cells appear as perifollicular infiltrates (clusters of immune cells around the hair follicle) in AA patients. In experiments, CD4+ T cells taken from AA-affected mice and injected under the skin of C3H\/HeJ mice induced generalized alopecia in the recipients. Research using the Dundee experimental bald rat model likewise points to CD4+ T cells as effectors of hair loss. Notably, CD8+ and CD4+ T cells contribute differently: \u003cstrong\u003eCD8+ T cells induce localized AA, while CD4+ T cells lead to systemic AA.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInvariant NK T cells (iNKT cells)\u003c\/strong\u003e are unconventional T lymphocytes that recognize lipid antigens such as α-galactosylceramide (α-GalCer) presented by CD1d molecules. They are \u003cstrong\u003e8- to 10-fold larger\u003c\/strong\u003e than both NK cells and conventional T cells, are abundant in killer cytokines, and bridge innate and adaptive immunity. In an animal model with human scalp skin xenografts, stimulating iNKT cells with α-GalCer halted the progression of AA lesions and promoted hair regrowth. This positions iNKT cells as potential therapeutic targets.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory T cells (Tregs)\u003c\/strong\u003e are immunosuppressive cells identified by the markers Foxp3, CD25, and CD4. They maintain immune balance. When Tregs are deficient in number or impaired in function, immune tolerance breaks down — a hallmark of autoimmune disease. Some studies show that IL-2, IL-10, and transforming growth factor-β (TGF-β) secreted by Tregs can suppress CD8+NKG2D+ T cells and reduce autoantigen production by hair follicle epithelial cells. The authors caution, however, that these findings remain inconclusive and need further study.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTissue-resident memory (TRM) T cells\u003c\/strong\u003e live permanently in tissues and act as a first line of defense against reinfection. They carry markers such as CD44, CD49, CD69, and CD103, and fall into two subsets: IFN-γ-producing TRM1 and IL-17-producing TRM17. Upon re-exposure to antigens, they rapidly release IFN-γ and TNF-α. This helps explain a familiar clinical pattern: \u003cstrong\u003erecurrent AA typically returns to the original site of hair loss\u003c\/strong\u003e, because T cell clones persist at the lesion. Studies show upregulation of CD103+CD69+ TRM T cells at lesion sites in AA patients. The authors conclude TRM cells have a substantial impact on both the development and recurrence of AA.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDendritic epidermal T cells (DETCs)\u003c\/strong\u003e are a specialized subset of γδ T cells. They share features with conventional αβ T cells, including upregulated NKG2D expression and the ability to secrete cytotoxic and inflammatory cytokines. Stimulated by self-antigens, they may participate in AA by producing IFN-γ that promotes CD8+NKG2D+ T cell activity and triggers the breakdown of hair follicle immune privilege. Observational study of hair follicles found DETCs rarely present in healthy skin but significantly elevated in AA patients. The authors note that further studies are needed to clarify their exact contribution.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOther cell types contribute as well.\u003c\/strong\u003e Mast cells and eosinophils infiltrate the skin lesions of AA patients:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMast cells\u003c\/strong\u003e sit near blood vessels and hair follicles. Their numbers correlate with CD8+ T lymphocytes around deep hair follicles. Infiltration in mesenchymal, perivascular, and perifollicular regions is more pronounced in AA patients than in healthy controls. Through degranulation (releasing their contents), cytokine release, and enhanced interaction with CD8+ T cells, mast cells worsen the inflammatory response.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEosinophils\u003c\/strong\u003e typically sit at the edges of enlarged AA lesions and can be present at all disease stages. They are found mainly around hair follicles during the late regressive and resting phases. Eosinophilic infiltration tends to be higher in patients with diffuse AA.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMelanocytes\u003c\/strong\u003e (pigment-producing cells) matter too. Melanin-associated antigens from follicular melanocytes activate CD8+NKG2D+ T cells, prompting their attack.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTogether, this collection of cells paints a complex picture of interacting immune activity around the hair bulb.\u003c\/p\u003e\n\n\u003ch2 id=\"cytokines\"\u003eCytokines: The Chemical Messengers Behind Hair Loss\u003c\/h2\u003e\n\n\u003cp\u003eCytokines are small signaling proteins that immune cells use to communicate. In AA, several play decisive roles.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIFN-γ (interferon-gamma)\u003c\/strong\u003e is a secreted glycoprotein of roughly \u003cstrong\u003e17 kDa\u003c\/strong\u003e (kilodaltons, a unit of molecular weight) and the only member of the type II interferon family. CD4+ T cells, CD8+ T cells, γδ T cells, and NK cells produce large amounts of it when stimulated by cytokines such as IL-12, IL-15, and IL-18. NK T cells, B cells, and antigen-presenting cells (APCs) make smaller amounts.\u003c\/p\u003e\n\n\u003cp\u003eIFN-γ activates macrophages, induces MHC-II-like molecule expression, and stands as one of the most important natural mediators of immune and inflammatory responses. It signals mainly through the \u003cstrong\u003eJAK–STAT pathways\u003c\/strong\u003e. It is considered a pivotal factor in breaking down the hair follicle's immune privilege.\u003c\/p\u003e\n\n\u003cp\u003eThe experimental evidence for IFN-γ is strong:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eWhen exogenous (externally given) IFN-γ was injected into female C3H\/HeJ mice, the treated mice developed hair follicle atrophy during the growth phase — something control mice rarely showed.\u003c\/li\u003e\n  \u003cli\u003eWhen skin from C3H\/HeJ mice with AA was transplanted into mice lacking the IFN-γ gene and into wild-type mice, \u003cstrong\u003e90% of the wild-type mice developed AA, while the IFN-γ-deficient mice did not develop the condition at all.\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eIn humans, affected skin of AA patients shows significantly enhanced IFN-γ-responsive gene expression compared with normal controls, and serum IFN-γ levels are markedly elevated in people with AA.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eTNF-α (tumor necrosis factor-alpha)\u003c\/strong\u003e is a \u003cstrong\u003e17.4 kDa\u003c\/strong\u003e proinflammatory cytokine produced mainly by macrophages and monocytes, but also by neutrophils, CD4+ T cells, and NK cells. Multiple studies consistently find elevated serum TNF-α levels and increased TNF mRNA in peripheral blood mononuclear cells of AA patients compared with healthy individuals. Notably, \u003cstrong\u003epatients with atopic AA (AA plus allergic conditions such as eczema or asthma) had even higher serum TNF levels\u003c\/strong\u003e than those without atopic AA. Higher TNF-α levels are also seen in patients with a \u003cstrong\u003eSALT score of 25% or greater\u003c\/strong\u003e compared with those below 25%; SALT (Severity of Alopecia Tool) is a standardized scale for measuring how much scalp hair has been lost. Disease duration also correlates positively with TNF-α expression.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIL-17 (interleukin-17)\u003c\/strong\u003e is a group of six structurally similar proinflammatory cytokines: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. They are made by CD4+ T cells, CD8+ T cells, neutrophils, NK cells, and γδ T cells. IL-17 recruits immune cells and its effects amplify when it coexists with other proinflammatory cytokines. IL-17-secreting cells are present across all AA types, with a \u003cstrong\u003ehigher prevalence in multiple patchy alopecia and lower occurrence in alopecia totalis\u003c\/strong\u003e, and they localize predominantly at the periphery of the hair follicle. Elevated Th17 cells and IL-17 are consistently observed in AA patients, with a direct correlation between serum IL-17A, IL-17E, and IL-17F levels and disease severity.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIL-2 (interleukin-2)\u003c\/strong\u003e is a key immune regulator — a single-chain polypeptide of \u003cstrong\u003e15.5 kDa\u003c\/strong\u003e — secreted mainly by CD4+ T cells after activation through T cell receptors (TCRs) and CD28 costimulatory signaling. It is also produced by CD8+ T cells, NK cells, NKT cells, and dendritic cells (DCs). Heterozygous mice deficient in IL-2 (mice carrying only one working copy of the gene) show reduced expression of IL-2, IL-4, IL-10, IL-12, IFN-γ, TNF-α, and TGF-β. When skin grafts from AA-affected C3H\/HeJ mice were transplanted into IL-2-deficient mice, AA progression slowed relatively.\u003c\/p\u003e\n\n\u003cp\u003eIn humans, AA patients have higher serum IL-2 levels than healthy controls, and their peripheral blood mononuclear cells contain higher levels of IL-2 mRNA. The number of bald plaques on the scalp, the degree of alopecia, and the length of the condition all correlate positively with serum IL-2 levels. One caveat: some studies suggest only patients with generalized AA show elevated serum IL-2, while those with localized AA show no significant change.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIL-15 (interleukin-15)\u003c\/strong\u003e is a strong proinflammatory cytokine that is structurally identical to IL-2. It is produced by monocytes, macrophages, fibroblasts, keratinocytes, mast cells, neuronal cells, and dendritic cells. A comprehensive transcriptional analysis of AA lesions in both humans and C3H\/HeJ mice revealed upregulation of the IL-15 gene, and \u003cstrong\u003eblocking the IL-15β receptor significantly slowed AA progression\u003c\/strong\u003e. AA patients also show increased expression of IL-15 and its receptor subunit IL-15Rα in hair follicles, along with elevated serum IL-15 levels. Serum IL-15 correlates positively with AA severity, establishing it as a pivotal signaling molecule in the disease.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIL-12 (interleukin-12)\u003c\/strong\u003e is a heterodimer — a protein built from two different parts: an α-subunit (IL-12p35) and a β-subunit (IL-12p40), the latter shared structurally with IL-23. IL-12 is active only when both subunits are present. It is produced mainly by dendritic cells, macrophages, and B cells in response to microbial pathogens. AA patients show significantly higher serum IL-12 levels and increased IL-12 mRNA in peripheral blood mononuclear cells compared with healthy controls. IL-12 levels in these cells correlate positively with the severity and duration of hair loss.\u003c\/p\u003e\n\n\u003cp\u003eBeyond these individual molecules, AA patients show significant presence of three broad cytokine families that contribute to the condition:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTh1 cytokines\u003c\/strong\u003e — IL-2, IFN-γ, TNF-α, IL-12, and IL-18\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTh2 cytokines\u003c\/strong\u003e — IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17E, IL-31, and IL-33\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTh17 cytokines\u003c\/strong\u003e — IL-17, IL-17F, IL-21, IL-22, and IL-23\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOther cytokines also play a critical role in maintaining hair follicle immune privilege and in restoring it once it has collapsed. The authors liken these protective molecules to a \"follicular IP security\" system.\u003c\/p\u003e\n\n\u003ch2 id=\"diagnosis\"\u003eHow Alopecia Areata Is Diagnosed and Measured\u003c\/h2\u003e\n\n\u003cp\u003eDiagnosis of AA rests primarily on clinical presentation — what the doctor sees and hears during the examination. There is no single blood test that confirms the disease.\u003c\/p\u003e\n\n\u003cp\u003eDoctors supplement the clinical assessment with several auxiliary tests:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHair pull test\u003c\/strong\u003e — gentle traction on a small group of hairs to see how many come out and at what growth phase\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDermoscopy\u003c\/strong\u003e — magnified examination of the scalp surface to identify characteristic patterns\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHistopathological examination\u003c\/strong\u003e — microscopic study of a small skin biopsy sample to look for perifollicular inflammation and other diagnostic features\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAssessing severity matters because treatment choices and prognosis depend on how much hair has been lost and how quickly. The review highlights recent advancements in severity assessment tools, including the \u003cstrong\u003eSALT score (Severity of Alopecia Tool)\u003c\/strong\u003e, which quantifies the percentage of scalp hair loss. A SALT score of 25% or higher appears to track with higher TNF-α levels, suggesting the tool captures real biological differences between milder and more severe disease.\u003c\/p\u003e\n\n\u003ch2 id=\"treatments\"\u003eConventional Treatments: What Has Been Used for Decades\u003c\/h2\u003e\n\n\u003cp\u003eTraditional AA therapy aims to calm the immune attack on the follicle. Several categories are in common use.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTopical contact sensitizers\u003c\/strong\u003e work by deliberately provoking a mild allergic reaction on the scalp, which redirects immune activity. The two named in the review are:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eDiphenylcyclopropenone (DPCP)\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eSquaric acid dibutylester (SADBE)\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlucocorticosteroids\u003c\/strong\u003e (steroid medications that suppress inflammation) are used both systemically (affecting the whole body) and topically (applied directly to the skin).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSystemic immunosuppressants\u003c\/strong\u003e are also commonly prescribed. These include:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eMethotrexate\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eAzathioprine\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eCyclosporine (CsA)\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBeyond these mainstays, several investigational approaches have been tried:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eCryotherapy (freezing treatment)\u003c\/li\u003e\n  \u003cli\u003eMethyl aminolevulinic acid-based photodynamic therapy (a light-activated treatment)\u003c\/li\u003e\n  \u003cli\u003eTopical calcineurin inhibitors (CNIs)\u003c\/li\u003e\n  \u003cli\u003eTopical prostaglandin analogs, such as latanoprost or bimatoprost\u003c\/li\u003e\n  \u003cli\u003ePulsed infrared diode laser therapy\u003c\/li\u003e\n  \u003cli\u003eAntihistamines\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors are candid about the shortcomings of these options. Many conventional treatments show \u003cstrong\u003elimited efficacy\u003c\/strong\u003e, cause \u003cstrong\u003eadverse effects\u003c\/strong\u003e, suffer from \u003cstrong\u003epoor compliance\u003c\/strong\u003e (patients find them hard to stick with), and carry \u003cstrong\u003ehigh relapse rates after discontinuation\u003c\/strong\u003e (hair loss returns once treatment stops). These limitations make rigorous clinical monitoring necessary — patients need regular follow-up.\u003c\/p\u003e\n\n\u003ch2 id=\"emerging\"\u003eEmerging Targeted Therapies: Biologics and Small Molecules\u003c\/h2\u003e\n\n\u003cp\u003eThe therapeutic landscape is shifting. Two categories of newer drugs show particular promise as targeted interventions for AA.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBiologics\u003c\/strong\u003e are engineered proteins designed to block specific immune pathways. \u003cstrong\u003eSmall-molecule drugs\u003c\/strong\u003e include two classes highlighted in the review:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJAK inhibitors\u003c\/strong\u003e — drugs that block the Janus kinase (JAK) signaling pathway\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePDE4 inhibitors\u003c\/strong\u003e — drugs that block phosphodiesterase 4 (PDE4)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eWhy does blocking JAK matter so much in AA? Because the JAK–STAT pathway sits directly at the center of the disease process. As described earlier, CD8+NKG2D+ T cells use JAK1 and JAK2 to produce IFN-γ, and they use JAK1 and JAK3 to respond to IL-15. Breaking this loop interrupts the self-sustaining cycle of inflammation.\u003c\/p\u003e\n\n\u003cp\u003eThe authors describe a clear advantage over traditional therapy. Compared with conventional treatments, biologics and small molecules:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003eAct rapidly\u003c\/li\u003e\n  \u003cli\u003eDemonstrate superior efficacy\u003c\/li\u003e\n  \u003cli\u003eEnable precise modulation of disease pathways\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe review characterizes this as a paradigm shift in AA management — a fundamental change in how the disease is approached. The review states that targeted therapies are poised to redefine treatment standards.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe most important practical message is that AA is an immune disease with identifiable molecular targets, not an unexplained cosmetic problem. That understanding is already changing treatment.\u003c\/p\u003e\n\n\u003cp\u003eSeveral implications follow directly from the science:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTargeted therapy is now possible.\u003c\/strong\u003e Because IFN-γ, IL-15, and the JAK–STAT pathway sit at the center of the disease, drugs that interrupt them address the underlying mechanism rather than just the symptom.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFaster results with better outcomes.\u003c\/strong\u003e The review reports that newer agents act rapidly and show superior efficacy compared with older options — and older options often fail, cause side effects, or stop working when discontinued.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRecurrence has a biological explanation.\u003c\/strong\u003e TRM T cells persist at the original lesion site, which is why AA tends to return in the same place. This helps patients understand why long-term monitoring may be needed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMental health is part of the disease.\u003c\/strong\u003e With psychological distress affecting nearly 60% of AA patients, and anxiety disorders more common in women, emotional support is not optional — it is part of comprehensive care.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScreening for related conditions matters.\u003c\/strong\u003e The elevated risk of other autoimmune disorders, hypertension, and hyperlipidemia means blood pressure and cholesterol monitoring are reasonable parts of a patient's overall care.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors also point out that AA affects all ages, genders, and ethnicities. AA appears more often in children than adults, and occurs at comparable rates in men and women. No patient group can be assumed to be at low risk.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What Researchers Still Cannot Explain\u003c\/h2\u003e\n\n\u003cp\u003eThe review is explicit about the gaps in knowledge. Several limitations stand out.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe precise etiology remains elusive.\u003c\/strong\u003e Etiology means cause. Despite significant advances in identifying contributing factors, researchers still cannot pinpoint what starts AA in any individual patient.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSubstantial gaps persist in understanding the full spectrum of molecular mechanisms.\u003c\/strong\u003e The disease involves immune dysregulation, genetics, epigenetics, hair cycle disturbance, and environmental influence — and how these interact is not fully mapped.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe Treg findings are inconclusive.\u003c\/strong\u003e Some studies link regulatory T cells to AA pathogenesis and show their secretions (IL-2, IL-10, TGF-β) can suppress CD8+NKG2D+ T cells. The authors state these findings warrant further investigation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe role of DETCs needs clarification.\u003c\/strong\u003e While DETCs are significantly elevated in AA patients compared with healthy individuals, their exact contribution to the disease remains undefined.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSome cytokine findings conflict.\u003c\/strong\u003e For IL-2, most studies show elevated levels in AA patients. Some research suggests only patients with generalized AA have elevated serum IL-2, while those with localized AA show no significant change.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCurative therapy does not yet exist.\u003c\/strong\u003e Current treatments provide symptomatic relief only, and the persistent limitations of conventional therapy — limited efficacy, adverse effects, poor compliance, and high relapse rates — leave patients with unmet needs.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003ePractical Recommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on what this review establishes, patients and families can take several concrete steps.\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGet a proper diagnosis from a dermatologist.\u003c\/strong\u003e AA is diagnosed primarily by clinical examination, supported when needed by a hair pull test, dermoscopy, or a scalp biopsy. Getting the diagnosis right matters because treatment differs by condition.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about disease severity and how it will be tracked.\u003c\/strong\u003e Tools such as the SALT score quantify how much scalp hair has been lost. Tracking this over time gives you and your doctor an objective way to judge whether a treatment is working.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss both conventional and targeted options.\u003c\/strong\u003e Conventional approaches — topical contact sensitizers such as DPCP and SADBE, topical or systemic steroids, and immunosuppressants such as methotrexate, azathioprine, and cyclosporine — remain in use. But ask specifically whether biologics or small-molecule drugs (JAK inhibitors, PDE4 inhibitors) might be appropriate, since the review reports they act faster and show superior efficacy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlan for the possibility of relapse.\u003c\/strong\u003e Relapse rates are high after stopping conventional treatment, and immune memory cells persist at the original site of hair loss. Ask your doctor what the follow-up plan is before you start any therapy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTreat the psychological side seriously.\u003c\/strong\u003e Nearly 60% of AA patients experience psychological distress, including anxiety, insomnia, and reduced self-esteem. Ask about mental health support as part of your care, not as an afterthought.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGet screened for related conditions.\u003c\/strong\u003e Because AA patients face higher risks of other autoimmune diseases, hypertension, and hyperlipidemia, regular blood pressure and cholesterol checks are reasonable.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBe patient with the science, but stay informed.\u003c\/strong\u003e The field is moving quickly, and the review frames targeted therapy as a paradigm shift. New options are emerging, and understanding the biology — especially why JAK and IL-15 pathways matter — can help you have a more productive conversation with your clinician.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eOne note of caution: this review summarizes research rather than prescribing individual treatment. Any decision about medication should be made with a qualified dermatologist who knows your history.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is alopecia areata?\u003c\/h3\u003e\n\u003cp\u003eAlopecia areata is an autoimmune condition in which the immune system mistakenly attacks hair follicles, causing patchy or complete hair loss that does not leave scars. It can affect the scalp, body, or both. It appears in several forms, from round bald spots to complete scalp hair loss (alopecia totalis) or loss of all scalp and body hair (alopecia universalis).\u003c\/p\u003e\n\u003ch3\u003eHow common is alopecia areata and who gets it?\u003c\/h3\u003e\n\u003cp\u003eAlopecia areata is the second most common hair loss disorder worldwide. It affects about 2% of the population, roughly 147 million people, and that number is projected to grow. It occurs in people of every age, gender, and ethnicity. Incidence is higher in children than adults, and rates are comparable between men and women.\u003c\/p\u003e\n\u003ch3\u003eWhat causes alopecia areata?\u003c\/h3\u003e\n\u003cp\u003eThe cause is multifactorial and not fully understood. Four forces interact: immune dysregulation, genetic susceptibility, environmental factors, and epigenetic changes. Hair follicles normally have an immune privilege that breaks down, exposing hidden hair follicle proteins to the immune system. This triggers inflammation driven by IFN-γ, CD8+ T cells, and other immune components, forcing follicles into premature resting phases.\u003c\/p\u003e\n\u003ch3\u003eHow is alopecia areata diagnosed?\u003c\/h3\u003e\n\u003cp\u003eDiagnosis rests mainly on clinical examination—what the doctor sees and hears. There is no single blood test that confirms the disease. Doctors may add a hair pull test, dermoscopy (magnified scalp examination), or a small scalp biopsy examined under a microscope. Severity is often tracked with the SALT score, which quantifies the percentage of scalp hair loss.\u003c\/p\u003e\n\u003ch3\u003eWhat treatments are available for alopecia areata?\u003c\/h3\u003e\n\u003cp\u003eConventional treatments include topical contact sensitizers (DPCP, SADBE), topical or systemic steroids, and immunosuppressants such as methotrexate, azathioprine, and cyclosporine. Newer targeted drugs include JAK inhibitors and PDE4 inhibitors. Compared with conventional treatments, these targeted therapies act rapidly and show superior efficacy. However, current treatments relieve symptoms but do not cure the disease.\u003c\/p\u003e\n\u003ch3\u003eWhat are the psychological effects of alopecia areata?\u003c\/h3\u003e\n\u003cp\u003ePsychological distress affects nearly 60% of patients—about 6 in 10. Reported problems include anxiety, insomnia, and diminished self-esteem, and these are most severe in patients with extensive hair loss. Anxiety-related disorders appear more often in women than in men. Emotional support is part of comprehensive care, not an afterthought.\u003c\/p\u003e\n\u003ch3\u003eDoes alopecia areata increase the risk of other health conditions?\u003c\/h3\u003e\n\u003cp\u003eYes. Patients face an elevated risk of other autoimmune disorders, hypertension (high blood pressure), and hyperlipidemia (high cholesterol and other blood fats). This means alopecia areata is not simply a cosmetic concern; it is a systemic condition with measurable effects on mental and physical health. Regular blood pressure and cholesterol checks are reasonable parts of overall care.\u003c\/p\u003e\n\u003ch3\u003eI was just diagnosed with alopecia areata and my dermatologist wants to start me on steroids — when should I get a second opinion?\u003c\/h3\u003e\n\u003cp\u003eConsider a second opinion when the diagnosis rests only on clinical examination without a hair pull test, dermoscopy, or scalp biopsy. Also consider a second opinion when conventional therapy is proposed without discussing targeted options. Conventional treatments show limited efficacy, adverse effects, poor compliance, and high relapse rates after discontinuation, while JAK inhibitors and PDE4 inhibitors act faster and show superior efficacy. Because severity tracking with the SALT score guides treatment choices, an independent review can confirm the diagnosis and whether newer agents are appropriate. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Alopecia Areata- Pathogenesis, Diagnosis, and Therapies\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Tianyou Ma, Tingrui Zhang, Fengze Miao, Jun Liu, Quangang Zhu, Zhongjian Chen, Zongguang Tai, and Zhigao He. Tianyou Ma and Tingrui Zhang contributed equally to this work.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthor affiliations:\u003c\/strong\u003e Department of Pharmacy, Longhua Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China; Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China; Shanghai Engineering Research Center of External Chinese Medicine, Shanghai, China.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCorresponding authors:\u003c\/strong\u003e Zhongjian Chen, Zongguang Tai, and Zhigao He.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e MedComm, 2025; volume 6, article e70182. Published by Sichuan International Medical Exchange \u0026amp; Promotion Association (SCIMEA) and John Wiley \u0026amp; Sons Australia, Ltd. This is an open-access article distributed under the terms of the Creative Commons Attribution License.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eArticle history:\u003c\/strong\u003e Received 9 October 2024; revised 17 March 2025; accepted 26 March 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e This work was supported by the National Natural Science Foundation of China (82172706 and 82373274), the Science and Technology Commission of Shanghai Municipality (22S21902700 and 23S21900800), and the Shanghai Municipal Health Commission (2024ZZ1009 and 202240370).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKeywords:\u003c\/strong\u003e alopecia areata, autoimmunity, diagnosis, pathogenesis, targeted therapy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47576666439836,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/ja\/products\/alopecia-areata-explained-a-patients-guide-to-autoimmune-hair-loss-diagnosis-and-modern-treatments","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}